LENZ Therapeutics (NASDAQ:LENZ) Earns Outperform Rating from Leerink Partnrs

Leerink Partnrs reiterated their outperform rating on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research report sent to investors on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q1 2024 earnings at ($0.51) EPS, Q2 2024 earnings at ($0.47) EPS, Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.80) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at $0.85 EPS and FY2028 earnings at $2.70 EPS.

Other equities research analysts also recently issued reports about the stock. Citigroup assumed coverage on shares of LENZ Therapeutics in a research report on Wednesday, April 10th. They issued a buy rating and a $34.00 price objective for the company. SVB Leerink started coverage on shares of LENZ Therapeutics in a research report on Monday. They set an outperform rating and a $32.00 price objective on the stock. Piper Sandler started coverage on shares of LENZ Therapeutics in a report on Wednesday, March 27th. They set an overweight rating and a $28.00 target price on the stock. Finally, William Blair began coverage on shares of LENZ Therapeutics in a report on Monday. They set an outperform rating on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of Buy and an average price target of $31.33.

LENZ Therapeutics Stock Down 11.1 %

LENZ stock opened at $17.70 on Monday. The firm has a market cap of $147.26 million, a PE ratio of -1.13 and a beta of 0.20. LENZ Therapeutics has a 52-week low of $14.07 and a 52-week high of $29.82.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. bought 998,009 shares of the stock in a transaction dated Thursday, March 21st. The shares were purchased at an average price of $15.03 per share, with a total value of $15,000,075.27. Following the completion of the acquisition, the director now owns 3,319,339 shares of the company’s stock, valued at $49,889,665.17. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 38.40% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.